
#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 1 year ago Tagged analysis antitrust biologics biosimilars competition economics generics intellectual property law litigation market payment pharmaceutical settlement
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 3 years ago Tagged antitrust biologics daraprim patent wars pay-for-delay pharmaceutical antitrust pharmaceuticals
Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]